在炎症性肠病患者中加用免疫调节剂抑制英夫利西单抗或阿达木单抗的抗药抗体
该回顾性研究收集英夫利西单抗或阿达木单抗血清浓度及抗药抗体,识别因免疫原性失去应答后加用免疫调节剂的患者。结果显示加用免疫调节剂可使部分患者抗药抗体降至检测不到、药物浓度升高并重获临床应答,作者认为换药前应考虑该策略。
要点
- 英夫利西单抗抗药抗体阳性98/376(26%),阿达木单抗阳性61/226(27%)。
- 加用免疫调节剂后17例中抗药抗体均降至检测不到,中位时间11个月。
- 硫嘌呤组6/10重获应答,甲氨蝶呤组7/7重获应答。
核心结论
- 在因免疫原性失去应答的炎症性肠病患者中,77%加用免疫调节剂后抗药抗体降至检测不到、血清药物浓度升高并重获临床应答,作者建议在换用其他药物前考虑该策略。
研究设计与样本
- 回顾性收集英夫利西单抗或阿达木单抗血清浓度和抗药抗体,识别抗药抗体阳性且失去应答后加用免疫调节剂的患者。
主要发现
- 英夫利西单抗抗药抗体阳性98/376(26%),阿达木单抗阳性61/226(27%)。
- 17/159例患者加用免疫调节剂;硫嘌呤组6/10重获临床应答,甲氨蝶呤组7/7重获临床应答。
- 英夫利西单抗组7/8例血清浓度升高(中位2.84 μg/mL;IQR:1.19-4.98),阿达木单抗组6/9例升高(中位3.10 μg/mL;IQR:1.45-4.45)。
- 抗药抗体降至检测不到的中位时间两种抗TNF药物均为11个月。
- 23例未加用免疫调节剂者中,缩短抗TNF间隔17/23、增加剂量6/23,分别有10/17和2/6重获临床应答。
临床怎么用
- 作者认为,在因免疫原性失去应答的炎症性肠病患者中,换用其他药物前应考虑加用免疫调节剂。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Loss of response to anti-tumour necrosis factor (TNF) therapy in patients with inflammatory bowel disease (IBD) is often caused by anti-drug antibody formation with neutralisation of drug effect. Addition of an immunomodulator has been suggested to reduce immunogenicity, leading to regained response. AIM: To investigate whether addition of an immunomodulator to anti-TNF monotherapy could lead to anti-drug antibody suppression and regained clinical response in IBD patients. METHODS: We retrospectively collected measurements of infliximab or adalimumab serum concentrations and anti-drug antibodies to identify anti-drug positive patients with loss response who were given an immunomodulator. RESULTS: Anti-drug antibodies against infliximab and adalimumab were detected in 98/376 (26%) and in 61/226 (27%) patients, respectively. Immunomodulators were given to 17/159 patients. Clinical response was recaptured in 6/10 patients receiving a thiopurine and in all (7/7) patients receiving methotrexate. In 7/8 patients on infliximab, serum concentrations increased (median 2.84 μg/mL; IQR: 1.19-4.98) and in 6/9 patients on adalimumab (median 3.10 μg/mL; IQR: 1.45-4.45). This was accompanied by a decrease in anti-drug antibodies to undetectable levels (median 11 months for both anti-TNF agents). In 23 patients, no immunomodulator was added but anti-TNF interval was shortened (17/23) or dosage was increased (6/23), which resulted in a clinical response in 10/17 and 2/6 patients, respectively. CONCLUSION: In 77% of IBD patients with loss of response due to immunogenicity, addition of immunomodulator resulted in undetectable anti-drug antibody levels, increased serum drug concentrations and regained clinical response. This strategy should be considered in this patient population before switching to other agents.
引用
- Strik AS, van den Brink GR, Ponsioen C, et al. Suppression of anti-drug antibodies to infliximab or adalimumab with the addition of an immunomodulator in patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2017. PMID: 28230306. doi:10.1111/apt.13994
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。